Newsroom

23

August 2017

Wednesday

iX Biopharma Ltd. has reported results for the fourth financial quarter ended 30 June 2017 (unaudited).

Meanwhile, the Group commenced a multi-dose Phase 2 efficacy study with Wafermine (KET010) in the USA.

More information can be found in the attached press releaseThe fourth quarter financial statements for the period can be found here.

15

May 2017

Monday

iX Biopharma Ltd. has incorporated a new wholly owned subsidiary, Entity Health Pte Ltd (“Entity”), to promote and market its new line of products: supplements addressing specific conditions. Entity will be the Group’s third business arm, complementing its existing pharmaceutical business and chemical analysis business.

More information can be found in the attached press release.

15

May 2017

Monday

Homegrown specialty pharmaceutical company iX Biopharma Ltd. is pleased to announce the results of BUP001, a pharmacokinetic study of its novel sublingual buprenorphine wafer, BnoX.

More information can be found in the attached press release.

11

May 2017

Thursday

iX Biopharma Ltd. has reported results for the third financial quarter ended 31 March 2017 (unaudited).

Meanwhile, the Group is currently making preparations to launch WafeRest™ in Singapore and the region in the second half of 2017. 

More information can be found in the attached press release. The third quarter financial statements for the period can be found here.

08

February 2017

Wednesday

iX Biopharma Ltd. has reported results for the second financial quarter ended 31 December 2016 (unaudited).

More information can be found in the attached press release. The first quarter financial statements for the period can be found here.

 

21

November 2016

Monday

Homegrown specialty pharmaceutical company iX Biopharma Ltd. is pleased to announce that it has been granted a patent in South Africa for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

11

November 2016

Friday

iX Biopharma Ltd. has reported results for the first financial quarter ended 30 September 2016 (unaudited).

More information can be found in the attached press release. The first quarter financial statements for the period can be found here.

31

October 2016

Monday

Homegrown specialty pharmaceutical company iX Biopharma Ltd. is pleased to announce that it has been granted a patent in Canada for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

13

September 2016

Tuesday

iX Biopharma Ltd. is pleased to announce the positive results of a pivotal bioequivalence study comparing iX Biopharma’s novel sildenafil wafer (PheoniX) with the reference drug.

More information can be found in the attached press release.

25

August 2016

Thursday

 iX Biopharma Ltd. has reported results for the fourth financial quarter and full year ended 30 June 2016 (unaudited).

More information can be found in the attached press release. The fourth quarter financial statements for the period can be found here.

 

For all company announcements, please refer to SGX company disclosures page.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com